集中癌症途径分析揭示了视网膜母细胞瘤中独特的治疗点
Sekaran Balaji1, Anindita Rao1, Karuvel Kannan Saraswathi1,2
1Department of Molecular Genetics, Aravind Medical Research Foundation, 1, Anna Nagar, Madurai, Tamil Nadu, 625 020, India.
Medical oncology (Northwood, London, England)
|June 4, 2024
概括
这项研究确定了68个失调的基因在视网膜母细胞瘤 (RB),儿童眼睛癌症. 细胞周期,血管新生和细胞亡途径的关键变化揭示了RB治疗的潜在新治疗标.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 视网母细胞瘤 (RB) 是一种常见的儿童眼癌,由RB1基因失活引起.
- 在RB中疾病的进展受到转录性改变的显著影响.
- 识别基因表达变化对于发现RB管理中的治疗点至关重要.
研究的目的:
- 为了研究视网膜母细胞瘤瘤中的基因表达特征.
- 为了确定参与RB病变的失调基因和途径.
- 发现潜在的分子点,以改善视网膜母细胞瘤治疗.
主要方法:
- 利用RT2 ProfilerTM PCR阵列对13个RB瘤中的84个癌症特异基因进行集中分析.
- 在另外15个RB瘤中使用RT-qPCR验证了关键转录变化.
- 从基因表达数据构建一个相互作用网络,以识别失调的途径.
- 通过Western blot证实了通过确定目标的蛋白质水平失调.
主要成果:
- 在分析的84个基因中,68个被发现在RB瘤中失调.
- 途径分析揭示了细胞周期,血管新生和亡途径的频繁干扰.
- 在所有瘤中观察到MCM2,MKI67,PGF,WEE1,CDC20的持续上调和COX5A的下调.
- 在侵袭性RB中,分子变化更为明显,与疾病发病发生相关.
结论:
- 该研究确定了显著的分子变化和视网膜母细胞瘤的潜在治疗点.
- 像MCM2,MKI67,PGF,WEE1,CDC20和COX5A这样的特定基因是RB进展中的关键参与者.
- PCR阵列技术为RB研究中的基因表达分析提供了一种快速且具有成本效益的方法.
相关概念视频
01:20The Retinoblastoma Gene
4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:54Canonical Wnt Signaling Pathway
8.7K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.7K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K